Heritability of circulating growth factors involved in the angiogenesis in healthy human population

被引:28
作者
Pantsulaia, I
Trofimov, S
Kobyliansky, E
Livshits, G [1 ]
机构
[1] Tel Aviv Univ, Human Populat Biol Res Unit, Dept Anat & Anthropol, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[2] Georgian Acad Sci, Dept Biomed, Inst Med Biotechnol, GE-380060 Tbilisi, Georgia
基金
美国国家科学基金会;
关键词
VEGF; EGF; TGF-beta; 1; TIMP-1; genetic correlation;
D O I
10.1016/j.cyto.2004.04.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The present study examined the extent of genetic and environmental influences on the populational variation of circulating growth factors (VEGF, EGF) involved in angiogenesis in healthy and ethnically homogeneous Caucasian families. The plasma levels of each of the studied biochemical indices were determined by enzyme-linked immunoassay in 478 healthy individuals aged 18-75 years. Quantitative genetic analysis showed that the VEGF and EGF variation was appreciably attributable to genetic effects, with heritability estimates of 79.9% and 48.4%, respectively. Yet, common environmental factors, shared by members of the same household, also played a significant role (P < 0.01) and explained between 20.1% and 32.6% of the variation. The present study additionally examined the covariations between these molecules and either transforming growth factor-beta1 (TGF-beta1) or tissue inhibitors of matrix metalloprotemases 1 (TIMP-1), likewise relevant for angiogenesis. Bivariate analysis revealed significant phenotypic correlations (P < 0.002) between all pairs of variables, thus indicating the possible existence of common genetic and environmental factors. The analysis suggested that the pleiotropic genetic effects were consistently the primary (or even the sole) source of correlation between all pairs of studied molecules. The results of our study affirm the existence of specific and common genetic pathways that commonly determine the greater part of the circulating variation of these molecules. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:152 / 158
页数:7
相关论文
共 42 条
[1]  
Benckert C, 2003, CANCER RES, V63, P1083
[2]   Tissue inhibitors of matrix metalloproteinases in cancer [J].
Blavier, L ;
Henriet, P ;
Imren, S ;
DeClerck, YA .
INHIBITION OF MATRIX METALLOPROTEINASES: THERAPEUTIC APPLICATIONS, 1999, 878 :108-119
[3]   Mechanisms of disease:: Role of transforming growth factor β in human disease. [J].
Blobe, GC ;
Schiemann, WP ;
Lodish, HF .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (18) :1350-1358
[4]   UNIVARIATE AND BIVARIATE ANALYSES OF CHOLESTEROL AND TRIGLYCERIDE LEVELS IN PEDIGREES [J].
BOEHNKE, M ;
MOLL, PP ;
LANGE, K ;
WEIDMAN, WH ;
KOTTKE, BA .
AMERICAN JOURNAL OF MEDICAL GENETICS, 1986, 23 (03) :775-792
[5]  
Distler JHW, 2003, Q J NUCL MED, V47, P149
[6]  
Falconer D.S., 1996, Quantitative Genetics, V4th
[7]   Role of vascular endothelial growth factor in Physiologic and Pathologic angiogenesis: Therapeutic implications [J].
Ferrara, N .
SEMINARS IN ONCOLOGY, 2002, 29 (06) :10-14
[8]   The biology of VEGF and its receptors [J].
Ferrara, N ;
Gerber, HP ;
LeCouter, J .
NATURE MEDICINE, 2003, 9 (06) :669-676
[9]  
Gerber HP, 1999, DEVELOPMENT, V126, P1149
[10]   Genetic control of the circulating concentration of transforming growth factor type β1 [J].
Grainger, DJ ;
Heathcote, K ;
Chiano, M ;
Snieder, H ;
Kemp, PR ;
Metcalfe, JC ;
Carter, ND ;
Spector, TD .
HUMAN MOLECULAR GENETICS, 1999, 8 (01) :93-97